Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

[1]  K. Chung,et al.  Safety and Tolerability of Indacaterol over 52 Weeks of Treatment in COPD. , 2009, ATS 2009.

[2]  V. Ninane,et al.  24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol , 2009, Current medical research and opinion.

[3]  A. Chuchalin,et al.  A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. , 2008, Respiratory medicine.

[4]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[5]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[6]  P. Chanez,et al.  Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .

[7]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop , 2007, Journal of biopharmaceutical statistics.

[8]  J. Bourbeau,et al.  Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.

[9]  H. Magnussen,et al.  Onset and Duration of Action of Formoterol and Tiotropium in Patients with Moderate to Severe COPD , 2006, Respiration.

[10]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[11]  J. Bourbeau,et al.  Tiotropium for stable chronic obstructive pulmonary disease , 2005 .

[12]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[13]  J. Bourbeau,et al.  Inhaled tiotropium for stable chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.

[14]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[15]  L. Forkert,et al.  Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. , 2002, Chest.

[16]  L. Forkert,et al.  Evaluation of bronchodilator responses in patients with “irreversible” emphysema , 2001, European Respiratory Journal.

[17]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[18]  K. P. Van de Woestijne,et al.  Mechanisms for isolated volume response to a bronchodilator in patients with COPD. , 2000, Journal of applied physiology.